Epineprhine auto injector carriers Discreet, Modern, Athletic Designs. Epipen waist sling, Epipen and AuviQ leg holster and cases for kids, teens, and adults
OmaxCare email
Home OmaxCare
In January 2013 Sanofi  announced  that Auvi-Q™ (epinephrine injection,
USP)
became  available in U.S. retail pharmacies nationwide with a
prescription from a healthcare provider.

Summary of information distributed when the announcement was
made:

Auvi-Q is the first-and-only epinephrine auto-injector with audio and
reactions in people who are at risk for or have a history of anaphylaxis.
Auvi-Q is the first-and-only epinephrine auto-injector with audio and
The size and shape of a credit card and the thickness of a smart visual
cues for the emergency treatment of life-threatening allergic phone,
Auvi-Q is a breakthrough in epinephrine auto-injector device design
that talks patients and caregivers step-by-step through the injection
process.

"Patient feedback was a critical component to the development
process for Auvi-Q," said Anne Whitaker, President, North America
Pharmaceuticals, Sanofi. "The availability of Auvi-Q represents an
important step forward in our continued innovation to meet the needs
of people at risk for anaphylaxis and their caregivers."
SANOFI AUVI-Q(TM)Up to six million Americans may be at risk for
anaphylaxis, although the precise incidence is unknown and likely
under-reported. While guidelines emphasize the importance of the life-
saving role of epinephrine, two large surveys  show that two-thirds of
patients and caregivers do not carry their epinephrine auto-injectors
as recommended, and nearly half worry that others will not know how
to use their or their child's epinephrine auto-injector correctly during
an emergency.

Multiple studies have found an association between delay in
epinephrine administration and death from anaphylaxis. Life-
threatening allergic reactions may occur as a result of exposure to
allergens including foods such as peanuts, tree nuts, fish, shellfish,
dairy, eggs, soy and wheat; insect stings; latex and medication, among
other allergens and causes.
Auvi-Q
access.
  • Dr's recommend you carry two epinephrine
    auto injectors at all times.
  • Self carry two  Auvi-Q inside secured pant
    pockets, an undergarment holder, or a
    carrier that can be attached or clip on to
    your clothing.
About Anaphylaxis
The signs and symptoms of anaphylaxis can vary from person to person and from one
makes it difficult to breathe or swallow, while others may experience nausea and vomiting.
These symptoms may begin within seconds, minutes or hours after exposure to the allergen.
administered immediately and patients and caregivers should seek immediate medical in
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes
therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of
healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative
drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is
listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Sanofi is the holding company of a consolidated group of subsidiaries and operates in the
United States as Sanofi US, also referred to as Sanofi-aventis U.S. LLC. For more
information on Sanofi US, please visit
Sanofi or call 1-800-981-2491.
Auvi-Q is for immediate self (or caregiver)
administration and does not take the
place of emergency medical care. Seek
immediate medical treatment after use.
epinephrine.

Auvi-Q should only be injected into your
BUTTOCK OR INTRAVENOUSLY. If you
accidentally inject Auvi-Q into any other
part of your body, seek immediate medical
treatment. Epinephrine should be used
with caution if you have heart disease or
are taking certain medicines that can
cause heart-related (cardiac) symptoms.

If you take certain medicines, you may
develop serious life-threatening side
effects from epinephrine. Be sure to tell
your doctor all the medicines you take,
especially medicines for asthma. Side
effects may be increased in patients with
certain medical conditions, or who take
certain medicines. These include asthma,
allergies, depression, thyroid disease,
Parkinson's disease, diabetes, high blood
pressure, and heart disease.
irregular heartbeat, sweating, nausea and
vomiting, difficulty breathing, paleness,
dizziness, weakness or shakiness, The
most common side effects may headache,
apprehension, nervousness, or anxiety.
These side effects go away quickly,
especially if you rest.
Talk to your healthcare professional to
see if Auvi-Q is right for you.
been studied in patients weighing less than 33 pounds. Each Auvi-Q pack contains two devices - containing one dose of epinephrine
each - and a non-active training device. Auvi-Q received U.S. Food and Drug Administration approval in August 2012.
Sanofi US licensed the North America commercialization rights to Auvi-Q from Intelliject, Inc., which has retained commercialization rights
for the rest of the world. Eric and Evan Edwards, twin brothers who suffer from life-threatening allergies, and co-founders of Intelliject, Inc.,
developed Auvi-Q with a team of world class engineers and scientists. The development process incorporated real-world experiences and
feedback from patients and caregivers.
Auvi-Q has been named an International CES Innovations 2013 Design and Engineering Awards Honoree. The prestigious Innovations
Design and Engineering Awards are sponsored by the Consumer Electronics Association (CEA)®, the producer of the International CES
auvi q legbuddy by omaxcare
epipens inside legbuddy by omaxcare
auviq cases and epipen cases for epinephrine auto injectors by omaxcare
marlena delgado coen